OncoCyte Corporation (OCX) - קצב צמיחת רווח למניה בשנה הנוכחית

The annual growth of OncoCyte Corporation (OCX) net income per share demonstrates yield dynamics, where 79.20 captures the current value of the indicator. OncoCyte Corporation (OCX) is valued by physicians for the accuracy of its precision tests. The business relies on automated genetic analysis of biomaterials. Demand for cancer screening remains stable regardless of economic crises or seasonality.

Steady demand for OncoCyte Corporation (OCX) oncology tests creates a predictable cash flow, which is reflected in the 12-month relative EPS growth rate. This metric measures the percentage change in net income per share compared to the same period last year, determining the business's scaling pace. Positive momentum confirms the effective monetization of clinical inertia, signaling a fundamental strengthening of the asset's value to the investor.